Virologists, doctors, experts in the field have been repeating this for days: we could be sure that we have defeated this one pandemic only if there is a vaccine. Unfortunately, the times will not be so immediate. For this you need to be careful and observe the rules for the safety. However, good news, all Italian, comes right on the vaccine to defeat Covid 19. In fact, experimentation on humans will begin this summer. ReiThera, a company based in Castel Romano, a district south of Rome, takes care of it. The distribution of the Italian vaccine, if the trial works, will in any case take place no earlier than 2021.
The Italian vaccine, a collaboration with Germany and Belgium
And once again it is Italy, therefore, to produce important steps in medicine. "ReiThera" will start testing the vaccine, developed within a European consortium together with Leokocare Ag of Munich and the Univercells Sa company of Brussels. A significant collaboration that seems to give hope for research. The production and distribution of vaccines on a large scale, ensures the consortium, but only after experimentation on man.
The vaccine will be available to healthcare professionals and vulnerable people
But the experimentation does not stop. Development of a vector-based “adenoviral vaccine” candidate targeting the SARS-CoV-2 spike protein has begun. One more step, therefore, on the vaccine which is based on a new adenoviral vector which is owned by ReiThera. The forecast for the production of the vaccine is also planned. It is estimated to have around 6 million doses since the beginning of next year. If the results of the experimentation are successful, the doses produced will be distributed to the most exposed categories first of all. Doctors and health personnel, highly vulnerable people.
The company's urgency to respond to the global emergency
Expectations are therefore very high. In fact, the company expects to complete the experimentation in a short time and thus be able to make an important contribution to defeat the pandemic. "Covid-19 has transformed our society on a global scale and has had a devastating effect in Italy in particular - said Stefan Colloca, Chief Technology Officer of ReiThera - we are eager to respond to the demands of our industry and society to join global efforts. against this rapidly spreading virus. Our experience and positive preclinical and clinical data on adenovirus vaccines allow us to react to this unprecedented situation in a timely manner.. We look forward to working with our partners, whose complementary skills and capabilities will help this new consortium respond as quickly as possible to this global health emergency. ”
